Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Progress in cardiovascular diseases

• Publication date

  2010-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.pcad.2010.05.005PMID 20728704PMCID PMC2956432
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The QT Interval

  2010cited by this paper
• QT as a Safety Biomarker in Drug Development

  2009cited by this paper
• Assessing proarrhythmic potential of drugs when optimal studies are infeasible.

  2009cited by this paper
• Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents

  2008cited by this paper
• If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?

  2008cited by this paper
• Concentration‐QT Relationships Play a Key Role in the Evaluation of Proarrhythmic Risk During Regulatory Review

  2008cited by this paper
• Drug-induced QT prolongation and proarrhythmia: an inevitable link?

  2007cited by this paper
• Compressing drug development timelines in oncology using phase '0' trials

  2007cited by this paper
• Molecularly targeted oncology therapeutics and prolongation of the QT interval.

  2007cited by this paper
• Safety biomarkers and the clinical development of oncology therapeutics: Considerations for cardiovascular safety and risk management

  2006cited by this paper
• Challenges of Evaluating the Cardiac Effects of Anticancer Agents

  2006cited by this paper
• Patients' decision-making process regarding participation in phase I oncology research.

  2006cited by this paper
• Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma

  2006cited by this paper
• Drug-induced torsades de pointes: the evolving role of pharmacogenetics.

  2005cited by this paper
• Cardiotoxicity of cancer therapy.

  2005cited by this paper
• Drug-induced prolongation of the QT interval.

  2004cited by this paper
• Drug-induced prolongation of the QT interval.

  2004cited by this paper
• Baseline heart rate-corrected QT and eligibility for clinical trials in oncology.

  2003cited by this paper
• Risk stratification in the long-QT syndrome.

  2003cited by this paper
• Risk stratification in the long-QT syndrome.

  2003cited by this paper
• Effect of arsenic trioxide on QT interval in patients with advanced malignancies.

  2003cited by this paper
• Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

  2003cited by this paper
• Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management.

  2002cited by this paper
• Drug Block of I Kr : Model Systems and Relevance to Human Arrhythmias

  2001cited by this paper
• Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes

  2001cited by this paper
• The QT interval.

  2001cited by this paper
• The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.

  2000cited by this paper
• QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience

  2000cited by this paper
• The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology.

  2000cited by this paper
• The QT Interval and Torsade de Pointes

  1999cited by this paper
• Cisapride‐Induced Torsades de Pointes

  1998cited by this paper
• Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events.

  1996cited by this paper
• QT-Interval prolonging drugs: Mechanisms and clinical relevance of their arrhythmogenic hazards

  1991cited by this paper

• Mobile/wearable digital devices for care of active cancer patients: a survey from the ESC Council of Cardio-Oncology

  2025cites this paper
• American ginseng vesicles loaded hyaluronic acid hydrogel for ulcerative colitis.

  2024cites this paper
• Cardio-Oncology Considerations in Oncologic Treatment Decisions

  2022cites this paper
• Intracellular Signaling Pathways Mediating Tyrosine Kinase Inhibitor Cardiotoxicity.

  2022cites this paper
• Association of QTc Formula With the Clinical Management of Patients With Cancer.

  2022cites this paper
• The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer

  2021cites this paper
• The Role of METTL3-Mediated N6-Methyladenosine (m6A) of JPH2 mRNA in Cyclophosphamide-Induced Cardiotoxicity

  2021cites this paper
• Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies

  2021cites this paper
• QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small‐Molecule New Drug Applications Approved During 2011‐2019

  2021cites this paper
• Turning liabilities into opportunities: Off-target based drug repurposing in cancer.

  2020cites this paper
• Cardiovascular effects of innovative therapies in lung cancer

  2020cites this paper
• Pseudo-colouring an ECG enables lay people to detect QT-interval prolongation regardless of heart rate

  2020cites this paper
• Pseudo-colouring ECGs enables lay people to detect drug-induced QT-prolongation regardless of heart rate: A multi-reader, multi-case ROC, psychophysical and eye-tracking study

  2020cites this paper
• Approach to initiating QT-prolonging oncology drugs in the ambulatory setting

  2019cites this paper
• Evaluating the Impact of Pseudo-Colour and Coordinate System on the Detection of Medication-induced ECG Changes

  2019cites this paper
• Risk Factors of QTc Prolongation in Women With Hormone Receptor‒positive/Human Epidermal Growth Factor Receptor 2‒negative Metastatic Breast Cancer: A Retrospective Analysis of Health Care Claims Data.

  2019cites this paper
• Onco-cardiology: Drug-drug interactions of antineoplastic and cardiovascular drugs.

  2019cites this paper
• QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care.

  2019cites this paper
• The Impact of Pazopanib on the Cardiovascular System

  2018cites this paper
• Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs.

  2018cites this paper
• Updates on managing advanced breast cancer with palbociclib combination therapy

  2018cites this paper
• Perioperative management of patients with congenital or acquired disorders of the QT interval

  2018cites this paper
• Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies

  2017cites this paper
• Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes

  2017cites this paper
• Cancer drugs and QT prolongation: weighing risk against benefit

  2017cites this paper
• Reduce the risk of QT interval prolongation associated with targeted cancer therapy by using arrhythmic risk stratification and prevention strategies

  2017cites this paper
• Reduce the risk of QT interval prolongation associated with targeted cancer therapy by using arrhythmic risk stratification and prevention strategies

  2017cites this paper
• QT prolongation due to targeted anticancer therapy

  2016cites this paper
• A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology

  2016cites this paper
• Arrhythmias and Other Electrophysiology Issues in Cancer Patients Receiving Chemotherapy or Radiation

  2016cites this paper
• Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management

  2016cites this paper
• Benefits of Centralized ECG Reading in Clinical Oncology Studies

  2016cites this paper
• Extreme doses of intravenous methadone for severe pain in two children with cancer

  2015cites this paper
• Current approach for detection of sub-clinical left ventricular dysfunction associated with chemotherapy

  2015cites this paper
• A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma

  2015cites this paper
• Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin

  2015cites this paper
• Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.

  2015cites this paper
• Assessment of the effect of ofatumumab on cardiac repolarization

  2015cites this paper
• Specific Clinic Problems in Cancer Therapy Cardiac Toxicity Complications

  2015cites this paper
• Pharmacological Treatment of Psychotic Disorders

  2014cites this paper
• A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumors

  2014cites this paper
• HERG-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs.

  2014cites this paper
• Widened QRS interval and left ventricular systolic depression after propafenone and promazine exposure.

  2014cites this paper
• Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors.

  2013cites this paper
• Chapter 13 – Pharmacokinetics and Safety Assessment

  2013cites this paper
• Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study

  2013cites this paper
• Safety and efficacy of vemurafenib in end stage renal failure

  2013cites this paper
• Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation

  2013cites this paper
• Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis

  2012cites this paper
• Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary

  2012cites this paper
• Developing new anti-cancer drugs.

  2011cites this paper
• Le alterazioni elettrocardiografiche espressione di cardiotossicità

  2011cites this paper